Progress in stopping bleeding in atrial fibrillation sufferers present process stenting
A brand new examine led by clinician-researchers at Beth Israel Deaconess Medical Middle (BIDMC) testing the security and effectiveness of anticoagulant methods for sufferers with atrial fibrillation who bear stenting procedures has proven that therapies combining the anticoagulant drug rivaroxaban with both single or twin anti-platelet remedy (DAPT) have been simpler in stopping bleeding problems than the present customary of care. Principal Investigator C . Michael Gibson, MD, Chief of Medical Analysis within the Division of Cardiovascular Medication at BIDMC, reported the brand new analysis findings on-line in The New England Journal of Medication and concurrently introduced the findings on the American Coronary heart Affiliation's Scientific Classes 2016 in New Orleans. The PIONEER AF-PCI randomized medical trial concerned greater than 2,100 sufferers at 430 websites in 26 international locations. Every year, almost 1 million sufferers i...